The technology based on cell or tissue cultures is very useful for the production of bioactive compounds. These molecules, depending on the class they belong to, can be used in the food, pharmaceutical and cosmetic industry. In particular, the developed technology is addressed to the optimization of bioactive compounds in plant cell/tissue cultures having the biosynthetic pathway of the compound of interest.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 16 - 30 of 50
INCIPIT technology allowed the implementation of a multifunctional, micro-structured and electroconductive therapeutic product to treat patients with myocardial infarction, the leading cause of death for cardiovascular disease. Current therapies (drugs, bypass, angioplasty) do not restore the functionality of damaged myocardial tissue.
The herein described technology aims at the development of a platform of injectable hydrogels for application as drug carriers for localized delivery or in the regenerative medicine field. The use of ad-hoc synthesized poly(ether urethane)s (PEUs) as hydrogel forming materials is a common property which characterizes all the systems belonging to this platform.
Extracellular vesicles produced by teratocarcinoma cells were isolated and characterized. Functional assays on glioblastoma (GBM) cell cultures showed the inhibitory effect of these vesicles on tumor cell migration, without inducing undesirable effects such as increased cell proliferation or chemotherapy resistance.
The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).
An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.
Portable robotic device for bilateral neuromotor rehabilitation. An appropriate mechanical structure and a series of interchangeable accessories suitably designed allow the execution of various motor gestures of the upper limbs, involving different articulations and muscles. The possibility of being used with both limbs contributes to the recovery of motor coordination and facilitates the mechanism of brain plasticity. Some rotary axes the device is equipped with are motorized and sensorized.
We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.
Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.
The NanoMicroFab infrastructure, support companies operating in the field of micro and nanoelectronics through the supply of materials, development of processes, design, fabrication and characterization of materials and devices. NanoMicroFab makes use of existing CNR facilities of the Institute of Microelectronics and Microsystems, the Institute of Photonics and Nanotechnologies and the Institute for the Structure of Matter and provides: • a complete line of development of devices based on wide band gap semiconductors.
Severe asthma or chronic obstructive pulmonary disease (COPD) are nowadays associated with a poor response to corticosteroids which led to the use of high-dose with consequent improved onset of side effects. The use of nanotechnologies can represent an innovative approach for the effective treatment of both asthma and COPD. The development of new nano-formulations involving the use of nanomaterials and specifically tailored to be inhaled offers numerous advantages over conventional inhaled dosage forms.
NANOINCICLO is a technology based on the use of nanostructured cyclodextrins (CDs) for the targeted delivery of drugs such as anticancer drugs, photodynamic drugs, anti-inflammatories, antivirals, antibacterials, nutraceuticals and metals with therapeutic and diagnostic properties. Successful CDs for the proposed technology are FDA-approved or in advanced pre-clinical investigational stage and include natural and functionalized, polymeric, and amphiphilic monomeric CDs.
The development of new materials with near-infrared emission (NIR, 700 – 1000 nm) represent an important target in the technological progress of innovative active components for OLED devices (including flexible ones), surveillance systems, autonomous driving, night vision sensors, fiber optic telecommunications and medical systems. In all these fields it still lacks a commercial NIR-OLED technology.
Therapeutic strategies targeting cell cycle in cancer have in general failed in the clinic since the drugs have lacked the therapeutic index required to achieve a robust response against cancer cells with little or no cytotoxic effect on normal cells. NEK6 kinase, which is implicated in cell cycle control, has recently emerged as an attractive target for the development of novel anticancer drugs with enhanced therapeutic index.
We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.